^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    DNAH9 (Dynein Axonemal Heavy Chain 9)

    i
    Other names: DNAH9, Dynein Axonemal Heavy Chain 9, KIAA0357, DNAH17L, Dnahc9, HL-20, HL20, DYH9, Dynein, Axonemal, Heavy Polypeptide 9, Axonemal Beta Dynein Heavy Chain 9, Ciliary Dynein Heavy Chain 9, DNAL1, DNEL1, Dynein, Axonemal, Heavy Polypeptide 17-Like, DNAH9 Variant Protein, CILD40
    Associations

    News

    Trials
    5ms
    Elevated N6-Methyladenosine (m6A)-RNA-Methylation During Oral Carcinogenesis. (PubMed, J Oral Pathol Med)
    Our study revealed that the level of m6A-RNA methylation in the epithelial tissues of OED and OSCC was higher than that in oral normal epithelium, suggesting that the methylation modification might be involved in the occurrence of OED and its progression to OSCC. Furthermore, hypermethylation and upregulated expression of C4B, DNAH9, and NCALD were associated with a favorable prognosis in these diseases.
    Journal
    |
    DNAH9 (Dynein Axonemal Heavy Chain 9)
    10ms
    Genetic and transcriptional insights into immune checkpoint blockade response and survival: lessons from melanoma and beyond. (PubMed, J Transl Med)
    This analysis identified potential molecular determinants of response and survival to ICI treatment. Insights from melanoma biomarker research hold significant promise for translation into other malignancies, guiding individualized anti-tumor immunotherapy.
    Journal • Checkpoint inhibition • Tumor mutational burden • PD(L)-1 Biomarker • IO biomarker
    |
    TMB (Tumor Mutational Burden) • DNAH9 (Dynein Axonemal Heavy Chain 9)
    over1year
    Identification of the cytoplasmic DNA-Sensing cGAS-STING pathway-mediated gene signatures and molecular subtypes in prostate cancer. (PubMed, BMC Cancer)
    The molecular subtypes mediated by the cGAS-STING pathway and the genetic risk score may aid in identifying potentially high-risk PCa patients who may benefit from pharmacologic therapies targeting the cGAS-STING pathway.
    Journal • Gene Signature
    |
    HRAS (Harvey rat sarcoma viral oncogene homolog) • ITGB6 (Integrin Subunit Beta 6) • AURKB (Aurora Kinase B) • MUC5B (Mucin 5B, Oligomeric Mucus/Gel-Forming) • STAT6 (Signal transducer and activator of transcription 6) • DNAH9 (Dynein Axonemal Heavy Chain 9) • SLC5A1 (Solute Carrier Family 5 Member 1)
    2years
    Identification of molecular characteristics of FUT8 and alteration of core fucosylation in kidney renal clear cell cancer. (PubMed, Aging (Albany NY))
    Two CF-related subtypes with distinct prognosis and TME were identified in KIRC. FUT8 exhibited elevated expression in KIRC samples.
    Journal
    |
    SETD2 (SET Domain Containing 2, Histone Lysine Methyltransferase) • DNAH9 (Dynein Axonemal Heavy Chain 9) • FUT8 (Fucosyltransferase 8)
    |
    SETD2 mutation
    2years
    Whole-exome sequencing of Nigerian benign prostatic hyperplasia reveals increased alterations in apoptotic pathways. (PubMed, Prostate)
    NGRn BPH contained significant germline alteration interactions (BRCA2_rs11571831 and TP53_rs1042522) and increased somatic alteration frequencies (LMTK2, LRP1, COL18A1, CABP1, and FKBP1C) that impact apoptosis. Normal prostate development is maintained by balancing apoptotic and proliferative activity. Dysfunction in either mechanism can lead to abnormal prostate growth. This work is the first to examine genomic sequencing in NGRn BPH and provides data that fill known gaps in the understanding BPH and how it impacts men of African ancestry.
    Journal • BRCA Biomarker
    |
    TP53 (Tumor protein P53) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • LRP1B (LDL Receptor Related Protein 1B) • PMS2 (PMS1 protein homolog 2) • BARD1 (BRCA1 Associated RING Domain 1) • HSD3B1 (Hydroxy-Delta-5-Steroid Dehydrogenase 3 Beta- And Steroid Delta-Isomerase 1) • LRP1 (LDL Receptor Related Protein 1) • PKD1 (Polycystin 1) • CACNA1A (Calcium Voltage-Gated Channel Subunit Alpha1 A) • DNAH9 (Dynein Axonemal Heavy Chain 9) • LMTK2 (Lemur Tyrosine Kinase 2) • PKHD1 (PKHD1 Ciliary IPT Domain Containing Fibrocystin/Polyductin) • PRKD1 (Protein Kinase D1)
    over2years
    Integrative Analysis of Single-Cell and Bulk RNA Sequencing Reveals Prognostic Characteristics of Macrophage Polarization-Related Genes in Lung Adenocarcinoma. (PubMed, Int J Gen Med)
    Moreover, qPCR confirmed that the expression of the prognosis genes was generally consistent with the results of the bioinformatic analysis. Seven MPRGs (RGS13, ADRB2, DDIT4, MS4A2, ALDH2, CTSH, and PKM) were identified as prognostic genes for LUAD and revealed the mechanisms of MPRGs at the single-cell level.
    Journal
    |
    ALDH2 (Aldehyde Dehydrogenase 2 Family Member) • COL1A1 (Collagen Type I Alpha 1 Chain) • ADRB2 (Adrenoceptor Beta 2) • BCLAF1 (BCL2 Associated Transcription Factor 1) • COL11A1 (Collagen Type XI Alpha 1 Chain) • DDIT4 (DNA Damage Inducible Transcript 4) • DNAH9 (Dynein Axonemal Heavy Chain 9) • ZKSCAN1 (Zinc Finger With KRAB And SCAN Domains 1)
    over2years
    Identification of prognosis-associated genes in locally advanced well-differentiated thyroid cancer using TCGA cohort analysis (ESMO 2023)
    Relevant pathways related to the 16 genetic markers could be therapeutic targets. Genetic analysis of locally advanced WDTC may predict clinical applications in patient survival.
    Metastases
    |
    CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • JAK2 (Janus kinase 2) • KDR (Kinase insert domain receptor) • CDKN2B (Cyclin Dependent Kinase Inhibitor 2B) • TIMP1 (Tissue inhibitor of metalloproteinases 1) • TFF3 (Trefoil factor 3) • DNAH9 (Dynein Axonemal Heavy Chain 9) • EIF1AX (Eukaryotic Translation Initiation Factor 1A X-Linked) • SERPINA1 (Serpin Family A Member 1)
    almost3years
    Gene signature developed for predicting early relapse and survival in early-stage pancreatic cancer. (PubMed, BJS Open)
    The newly constructed support vector machine signature precisely and powerfully predicted relapse and survival in patients with stage I-II pancreatic ductal adenocarcinoma after R0 resection.
    Journal • Gene Signature
    |
    TP53 (Tumor protein P53) • DNAH9 (Dynein Axonemal Heavy Chain 9)
    |
    TP53 mutation
    almost3years
    A necroptosis gene signature predicts prostate cancer recurrence, and is linked to somatic mutation, therapeutic landscape, and immune infiltration. (PubMed, Am J Transl Res)
    Altogether, the necroptosis gene signature may effectively predict prostatic carcinoma recurrence and therapeutic responses, but its clinical feasibility must be verified.
    Journal • Tumor mutational burden • Gene Signature • IO biomarker
    |
    TP53 (Tumor protein P53) • TMB (Tumor Mutational Burden) • BCL2 (B-cell CLL/lymphoma 2) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2) • TSC1 (TSC complex subunit 1) • BCL2L11 (BCL2 Like 11) • PLK1 (Polo Like Kinase 1) • TNFRSF1A (TNF Receptor Superfamily Member 1A) • CASP8 (Caspase 8) • DNAH9 (Dynein Axonemal Heavy Chain 9) • HDAC9 (Histone Deacetylase 9)
    |
    TP53 mutation • TSC1 mutation
    almost3years
    Identification of hub genes associated with head and neck squamous cell carcinoma by integrated bioinformatics approach and RNA-seq validation analysis. (PubMed, Am J Cancer Res)
    Moreover, this study also revealed some novel links between DNAH1, DNALI1, DNAH9, and CCDC151 expression and genetic alterations, promoter methylation status, immune cell infiltration, miRNAs, gene enrichment terms, and various chemotherapeutic drugs. In conclusion, we indicated four hub genes (DNAH1, DNALI1, DNAH9, and CCDC151) and their associated signaling pathways, which may improve our understanding of HNSC and could be used as new therapeutic targets.
    Journal
    |
    DNAH9 (Dynein Axonemal Heavy Chain 9)
    almost3years
    Molecular Pathology of Micropapillary Carcinomas: Is Characteristic Morphology Related to Molecular Mechanisms? (PubMed, Appl Immunohistochem Mol Morphol)
    Prediction of prognosis and targeted therapy may benefit from the understanding of molecular mechanisms of micropapillary morphology. This review describes the molecular pathologic mechanisms underlying the micropapillary changes of cancers in various organs in a cell polarity-related dimension.
    Journal
    |
    EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • TP53 (Tumor protein P53) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • FGFR1 (Fibroblast growth factor receptor 1) • AKT1 (V-akt murine thymoma viral oncogene homolog 1) • CCND1 (Cyclin D1) • APC (APC Regulator Of WNT Signaling Pathway) • CDH1 (Cadherin 1) • RAC1 (Rac Family Small GTPase 1) • RHOA (Ras homolog family member A) • FOXO3 (Forkhead box O3) • JAG1 (Jagged Canonical Notch Ligand 1) • SNAI2 (Snail Family Transcriptional Repressor 2) • ZEB1 (Zinc Finger E-box Binding Homeobox 1) • DNAH9 (Dynein Axonemal Heavy Chain 9) • ITGA1 (Integrin Subunit Alpha 1) • ITGB1 (Integrin Subunit Beta 1) • OCLN (Occludin)
    |
    TP53 mutation • BRAF mutation • PIK3CA mutation • HER-2 mutation • APC mutation • MYC expression • FGFR1 expression • TP53 expression